1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016


DelveInsight’s Report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Report is to understand the market and pipeline status of the drugs around the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- A review of the marketed products under prescription for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs.
- Coverage of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- API intelligence over marketed drugs forHormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancerand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Illustrative Table of contents
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, Europe by Country, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, India by State, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, China by Province, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers by Geography 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2016
- Phase III Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, 2016
- Discontinued Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, 2016

List of Figures

- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, Europe by Country, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, India by State, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, China by Province, 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers by Geography 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

Insulin Market in the US

  • December 2016
    8 pages
  • Insulin  

  • United States  

View report >

Related Market Segments :

Hormone
Prostate Cancer

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.